MRNA-1283 explained
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna.
Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers.[2] Additionally, the vaccine will be packaged in prefilled syringes, reducing burden on healthcare workers and potentially increasing access.[3]
Clinical Trial
In December, Moderna started a clinical trial which would evaluate the vaccine's ability to provoke an immune response and its safety.[4] As of May 2024, the vaccine candidate is in Phase 3 clinical trials, with an estimated completion date of late August 2024.[5] Preliminary results from this trial indicated the vaccine produced a strong immune response, especially in patients over 65, who are at greater risk for severe outcomes from COVID-19.[6]
Notes and References
- News: Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day . 29 April 2022 . Bloomberg . 9 September 2021.
- Web site: Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine . news.modernatx.com. 30 May 2024.
- Web site: Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine . news.modernatx.com. 30 May 2024.
- Yassini P, Hutchens M, Paila YD, Schoch L, Aunins A, Siangphoe U, Paris R . Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults . Human Vaccines & Immunotherapeutics . 19 . 1 . 2190690 . December 2023 . 37074202 . 10128428 . 10.1080/21645515.2023.2190690 .
- Web site: A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE) . ClinicalTrials.org . 30 May 2024.
- Web site: Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine . news.modernatx.com. 30 May 2024.
